Your account is not claimed yet. You can sign up with ORCID to claim your account.

Xing Huang

Loop profile ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 33

Top Venues

Hepatology communications

Signal transduction and targeted therapy

Journal for immunotherapy of cancer

Autophagy

Zhejiang University

University of Science and Technology of China (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Zhejiang University Dec 1o 2018

China

Professor :: Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, School of Medicine

Education History

University of Science and Technology of China Sep 1o 2008 - Jun 30o 2013

China

PHD :: School of Life Sciences

Publications

Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen, Jianpeng Sheng, Xing Huang, Jun-Hui Sun, Wen-Bo Xiao, Ke Sun, Shunliang Gao, Risheng Que, Yan Shen, Min Zhang, Jian Wu, Xue-Li Bai, Jianpeng Sheng
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatology communications 7 (3) (2023)
Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen, Jianpeng Sheng, Xing Huang, Jun-Hui Sun, Wen-Bo Xiao, Ke Sun, Shunliang Gao, Risheng Que, Yan Shen, Min Zhang, Jian Wu, Xue-Li Bai, Jianpeng Sheng
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatology communications 7 (3) (2023)
Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen, Jianpeng Sheng, Xing Huang, Jun-Hui Sun, Wen-Bo Xiao, Ke Sun, Shunliang Gao, Risheng Que, Yan Shen, Min Zhang, Jian Wu, Xue-Li Bai, Jianpeng Sheng
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatology communications 7 (3) (2023)
Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen, Jianpeng Sheng, Xing Huang, Jun-Hui Sun, Wen-Bo Xiao, Ke Sun, Shunliang Gao, Risheng Que, Yan Shen, Min Zhang, Jian Wu, Xue-Li Bai, Jianpeng Sheng
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatology communications 7 (3) (2023)
Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen, Jianpeng Sheng, Xing Huang, Jun-Hui Sun, Wen-Bo Xiao, Ke Sun, Shunliang Gao, Risheng Que, Yan Shen, Min Zhang, Jian Wu, Xue-Li Bai, Jianpeng Sheng
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatology communications 7 (3) (2023)
Tianyu Tang, Xing Huang, Minghao Lu, Gang Zhang, Xu Han, Jianpeng Sheng
Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner. Nature communications 14 (1) (2023)
Gang Zhang, Tianyu Tang, Yinfeng Chen, Xing Huang, Jianpeng Sheng
mRNA vaccines in disease prevention and treatment. Signal transduction and targeted therapy 8 (1) (2023)
Tian-Yu Tang, Xing Huang, Gang Zhang, Minghao Lu, Zhengtao Hong, Meng Wang, Junming Huang, Xiao Zhi, Jianpeng Sheng
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. Journal for immunotherapy of cancer 10 (3) (2022)
Qianying Guo, Hao Wang, Jiahao Duan, Wenwu Luo, Rongrong Zhao, Yuting Shen, Bijun Wang, Siqi Tao, Yi Sun, Qian Ye, Xiaomin Bi, Hui Yuan, Qiang Wu, Peter E Lobie, Tao Zhu, Sheng Tan, Xing Huang, Zheng-Sheng Wu
An Alternatively Spliced p62 Isoform Confers Resistance to Chemotherapy in Breast Cancer. Cancer research 82 (21) (2022)
Tianyu Tang, Xing Huang, Gang Zhang, Tingbo Liang
Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity. Journal for immunotherapy of cancer 10 (7) (2022)
Tian-Yu Tang, Xing Huang, Gang Zhang, Ming-Hao Lu, Ting-Bo Liang
mRNA vaccine development for cholangiocarcinoma: a precise pipeline. Military Medical Research 9 (1) (2022)
Xing Huang, Gang Zhang, Tingbo Liang
Cancer environmental immunotherapy: starving tumor cell to death by targeting TGFB on immune cell. Journal for immunotherapy of cancer 9 (6) (2022)
Xing Huang, Gang Zhang, Tian-Yu Tang, Xiang Gao, Ting-Bo Liang
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Military Medical Research 9 (1) (2022)
Xing Huang, Gang Zhang, Tianyu Tang, Tingbo Liang
Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Molecular cancer 20 (1) (2021)
Xing Huang, Gang Zhang, Tingbo Liang
Pancreatic tumor initiation: the potential role of IL-33. Signal transduction and targeted therapy 6 (1) (2021)
Gang Zhang, Xing Huang
Killing HIV-infected resting central memory CD4+ T cells by targeting inhibitor of apoptosis proteins-inhibited autophagy. Antiviral chemistry & chemotherapy 29 (2021)
Xiaozhen Zhang, Xing Huang, Jian Xu, Enliang Li, Mengyi Lao, Tianyu Tang, Gang Zhang, Chengxiang Guo, Xiaoyu Zhang, Wen Chen, Dipesh Kumar Yadav, Xue-Li Bai, Tingbo Liang
NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nature communications 12 (1) (2021)
Tianyu Tang, Xing Huang, Gang Zhang, Zhengtao Hong, Xueli Bai, Tingbo Liang
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal transduction and targeted therapy 6 (1) (2021)
Xing Huang, Tianyu Tang, Gang Zhang, Tingbo Liang
Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Molecular cancer 20 (1) (2021)
Xing Huang, Xiaozhen Zhang, Xueli Bai, Tingbo Liang
Eating self for not be eaten: Pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation. Signal transduction and targeted therapy 5 (1) (2020)
Xing Huang, Gang Zhang, Xueli Bai, Tingbo Liang
Reviving the role of MET in liver cancer therapy and vaccination: an autophagic perspective. Oncoimmunology 9 (1) (2020)
Xing Huang, Tianyu Tang, Gang Zhang, Zhengtao Hong, Jian Xu, Dipesh Kumar Yadav, Xue-Li Bai, Jianpeng Sheng
Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. NPJ precision oncology 4 (1) (2020)
Xing Huang, Tianyu Tang, Xun Wang, Xueli Bai, Tingbo Liang
Calreticulin couples with immune checkpoints in pancreatic cancer. Clinical and translational medicine 10 (1) (2020)
Honglei Jin, Jiugao Ma, Jiheng Xu, Hongyan Li, Yuanyuan Chang, Nan Zang, Zhongxian Tian, Xin Wang, Nannan Zhao, Lu Liu, Caiyi Chen, Qipeng Xie, Yongyong Lu, Zhouxi Fang, Xing Huang, Chuanshu Huang, Haishan Huang
Oncogenic role of MIR516A in human bladder cancer was mediated by its attenuating PHLPP2 expression and BECN1-dependent autophagy. Autophagy 17 (4) (2020)
Xing Huang, Xiaozhen Zhang, Enliang Li, Gang Zhang, Xun Wang, Tianyu Tang, Xueli Bai, Tingbo Liang
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. Journal of hematology & oncology 13 (1) (2020)
Xing Huang, Xingyuan Xu, Xun Wang, Tianyu Tang, Enliang Li, Xiaozhen Zhang, Jian Xu, Hang Shen, Chengxiang Guo, Tao Xu, Jianhong Ren, Xueli Bai, Tingbo Liang
The AKT-independent MET-V-ATPase-MTOR axis suppresses liver cancer vaccination. Signal transduction and targeted therapy 5 (1) (2020)
Xing Huang, Qi Zhang, Yu Lou, Junli Wang, Xinyu Zhao, Lin Wang, Xiaozhen Zhang, Shanshan Li, Yulan Zhao, Qi Chen, Tingbo Liang, Xueli Bai
USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity. Cancer immunology research 7 (10) (2019)
Xing Huang
Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase-estrogen receptor axis. Clinical and translational medicine 8 (1) (2019)
Qi Zhang, Yu Lou, Jiaqi Yang, Junli Wang, Jie Feng, Yali Zhao, Lin Wang, Xing Huang, Qihan Fu, Mao Ye, Xiaozhen Zhang, Yiwen Chen, Ce Ma, Hongbin Ge, Jianing Wang, Jiangchao Wu, Tao Wei, Qi Chen, Junqing Wu, Chengxuan Yu, Yanyu Xiao, Xinhua Feng, Guoji Guo, Tingbo Liang, Xue-Li Bai
Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut 68 (11) (2019)
Xing Huang, Guangming Gan, Xiaoxiao Wang, Ting Xu, Wei Xie
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy 15 (7) (2019)
Xing Huang, Xiaozhen Zhang, Xueli Bai, Tingbo Liang
Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget. Cellular & molecular immunology 17 (7) (2019)
Zhipeng Su, Yunchun Han, Qichen Sun, Xiaoxiao Wang, Ting Xu, Wei Xie, Xing Huang
Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance. Molecular cancer therapeutics 18 (1) (2018)
Xing Huang
The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC. Journal of experimental & clinical cancer research : CR 37 (1) (2018)

Xing Huang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Xing Huang